This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. More interchangeable biosimilars are estimated to be approved and launched in the US in the next few years.
It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. A second, “transitional era” from 2000-2015 was one of older specialty products, including those in multiple sclerosis, early immunological biologics, and oncologics.
Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). In our healthcare space, however, improved understanding and practice of diversity is required and urgent—and the only way we’ll advance medicine equitably.
Sixty percent of employees in a recent survey reported experiencing healthcare cost increases that outpaced inflation in the past three years, and 63 percent expect that trend to continue, signaling potential cost challenges in the future. Right now, annual raises are being neutralized by increasing healthcare insurance premiums.
More companies are making high-quality healthcare easier to access and more affordable by embracing data and technology. While healthcare has historically been among the slowest to accept new technologies, the pandemic has sped adoption. What is personalized healthcare, and how can you incorporate it into your marketing strategy?
In some instances, the off-course message is about healthcare. Experienced marketing professionals and healthcare communicators recognize and avoid this classic mistake. Older Americans—sometimes labeled as Baby Boomers or (perilously as) Senior Citizens—are a vital target audience for healthcare marketing. Is 50 a senior age?
healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. CVS’ bid for Oak Street is in keeping with nearly two decades of evolution toward becoming an integrated payer and provider.
The need to attract new patients through digital means is forcing healthcare into a new era of on-demand patient consumerism. The development of new platforms and technologies drive healthcare organizations to adapt in an effort to give consumers of our services exactly what they want. Improve the work life of healthcare providers.
We have put together the top 5 tips and benefits of social networking for those in the medical and healthcare industry. And along came some competition – facebook, twitter, google+, linkedin…. In 2015, we performed a case study of the Impact of Social Media on website rankings. Build Your Brand.
Unique, relevant and quality content will provide the medical and healthcare related business a competitive edge. The image above reflects nearly 3,000 retweets and favorites from a single post (tweet) we did on January 20, 2015. The post Branding Medical and Healthcare Websites with Content appeared first on MedCepts.
Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.
By the end of the decade, two cell and gene therapies will be subject to follow-on competition for the first time, beginning a whole new chapter in the biosimilar history. Over time, patient volumes (patient treatment days) and levels of competition, including market share, were also considered. 6 billion in 2024 alone).
border healthcare, specifically by repealing Article 15, which originally laid down the modalities and principles for co-operation between Member States in assessing new health technologies. governmental healthcare organisations. Vincenzo Salvatore is of counsel and leader of the Healthcare and Life Sciences Focus Team at BonelliErede.
The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. These issues will be explored in the final article of this series.
The move from fee-for-service to value-based reimbursement is a sea change for the healthcare industry. The goals are to increase quality, decrease costs and turn health care into a competitive marketplace. They cite a 24% increase in drug costs per hospital admission in 2014 and a 12% increase in 2015.
The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.
Strong competition limits Sandoz's growth. Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition. stake in their consumer healthcare joint venture for $13bn.
Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. The biosimilar market in the US may progress differently this time.
Analyzing historical trends for the past 10 years reveals that the number of Indian paragraph IV filers continues to grow, while the number of filers in the United States has been stable since 2015. While Mainland China has only been involved in paragraph IV filings since 2015, this volume is increasing significantly.
Today’s healthcare consumers are seeking a different kind of healthcare experience. Patients want more control over their healthcare choices and transparency into the cost and quality of services they receive. Alternative payment models were introduced as part of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
Then between 2005-2015, there were 110 global blockbuster launches, with a high concentration in specialty care and biologics. With these launches came more complex science, which pushed biopharma’s evolution to integrate more medical engagement alongside the existing commercial focus for healthcare providers and payers.
” Niall Brennan Chief Privacy and Analytics Officer, Head of The Clarify Health Institute Raw price transparency data contains trillions of records, is inconsistently formatted, includes gaps in reporting, and paints a convoluted picture of healthcare pricing in the commercial market today.
With VR simulations, sales reps can now hone their skills in lifelike scenarios, giving them a competitive edge in the field. But VR’s potential doesn’t stop there; it’s poised to revolutionize everything from healthcare to education. I landed this competitive scholarship at the National Cancer Institute at school.
For example, starting in 2015 at Ogilvy, I watched companies that had been using print materials in doctors’ offices begin switching to large electronic tablets in waiting and exams rooms that displayed information for multiple brands. This is a synthesis of the growing research applying nudges in healthcare.
Founded 2015. Kyruus is revolutionizing healthcare with its data-driven system that makes it easier for healthcare system to match patients to appropriate providers. Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. 6 River Systems. 51-100 employees. $46
“There’s a huge clinical need which has been undelivered for years,” says Gustav Ando, manager of the healthcare business development unit [HBDU] at Global Insight. Analysts predict Pfizer’s revenue stream would be slashed by 25% by 2015 if the company did not branch out into other areas.
Healthcare Provider (HCP) marketing. Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. The post The evolving role of social media in healthcare appeared first on.
A couple of years ago, I first wrote about how social media’s role in the Pharma and healthcare sectors has been growing exponentially. Healthcare Provider (HCP) Marketing. In the same vein, patient advocates and influencers might share their personal journeys and help raise awareness of their condition and healthcare needs.
Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. In 2017, FDA announced the Drug Competition Action Plan (DCAP) to allow consumers to get access to medicines. These medicines comprise about 10% of all generics approved each year.
The FDA initially granted Orkambi approval in 2015 as the first medicine to treat the underlying cause of CF for individuals aged 12 or older with two copies of the F508del mutation. Health Canada previously approved Orkambi for CF patients ages two and above. This label expansion follows a similar label change in the US in September 2022.
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.
Uptake of mobile healthcare, wearable devices and web-based technologies meant decentralised clinical trials made up 30% of overall trials in 2021 – an increase of 9% since 2015. Virtual trials increased 50% year on year between 2020 and 2021 and evidence suggests the frontiers of the global clinical trial map are expanding.
Uptake of mobile healthcare, wearable devices and web-based technologies meant decentralised clinical trials made up 30% of overall trials in 2021 – an increase of 9% since 2015. Virtual trials increased 50% year on year between 2020 and 2021 and evidence suggests the frontiers of the global clinical trial map are expanding.
AARP recently found that the average annual cost for one brand name medication used on a chronic basis was $6,604 in 2020, more than $1,500 higher than the average annual cost of therapy in 2015. Senator Amy Klobuchar has proposed the Competition and Antitrust Law Enforcement Reform Act. For the average older American taking 4.7
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content